Satake Multi-Mix Co., Ltd. (Toda City, Saitama Prefecture, President and CEO Mitsutoshi Nishioka, hereinafter referred to as "our company") announces that we have begun delivering a total of 58 units, including our cultivation equipment, to Takara Bio Inc.'s (Kusatsu City, Shiga Prefecture, President and CEO Tsuyoshi Miyamura) "Gene and Cell Processing Center Building 3 (hereinafter referred to as CGCP III)". For details, please click here. CGCP III was selected in September 2022 for the "Project for the Development of Biopharmaceutical Manufacturing Bases, etc. for Strengthening Vaccine Production Systems," an initiative by the Ministry of Economy, Trade and Industry, and is a facility being constructed as part of the development project for both "vaccine manufacturing bases" and "manufacturing bases for raw materials and components." Please refer to the following for Takara Bio Inc.'s news release regarding the construction of CGCP III. Construction of Gene and Cell Processing Center Building 3 for Manufacturing mRNA Vaccine APIs and Raw Materials | News | Takara Bio Inc. Details about CGCPIII are also featured in the July issue of "PHARM TECH JAPAN," published on July 1st. [Contact Information] Satake Multi-Mix Co., Ltd. Advertising and Public Relations T 60 Niizo, Toda City, Saitama Prefecture, 335-0021 (within the Stirring Technology Research Institute) Email: info@satake.co.jp Website: https://www.satake.co.jp